A COMPREHENSIVE REVIEW OF EMPAGLIFLOZIN AND TOPIRAMATE IN THERAPEUTICS, DRUG DEVELOPMENT AND ANALYTICAL SCIENCES

Empagliflozin, a selective sodium–glucose co-transporter 2 (SGLT2) inhibitor, and Topiramate, an antiepileptic drug with weight-reduction potential, have emerged as clinically important agents in diverse therapeutic areas. Empagliflozin has demonstrated efficacy in type 2 diabetes, cardiovascular protection, and chronic kidney disease, while Topiramate has utility in Obesity epilepsy, migraine prophylaxis, and psychiatric disorders. Recent studies highlight potential synergistic benefits in weight management when used in combination. This review comprehensively examines their pharmacology, drug development history, analytical methods, therapeutic applications, safety, and future perspectives. Analytical sciences have contributed robust HPLC and LC–MS/MS methods for Empagliflozin quantification, while validated methods like HPLC, LC–MS/MS, GC–MS, CE, HPTLC, and spectrophotometry also exist for Topiramate. This article integrates advances across therapeutics, regulatory development, and analytical sciences to provide a holistic understanding of these two agents.